Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/04/2026 | Q4 | $12.1B | -- | -- | -- | -- |
| 11/05/2025 | Q3 | $11.9B | $11.7B | $0.70 | -- | -- |
| 08/06/2025 | Q2 | $12B | $11.7B | $0.91 | -- | -- |
| 05/07/2025 | Q1 | $11.9B | $11B | $0.92 | -- | -- |
| 02/05/2025 | Q4 | $11.5B | $12.3B | $0.91 | -- | -- |
| 11/06/2024 | Q3 | $10.5B | $10.5B | $0.90 | -- | -- |
| 08/07/2024 | Q2 | $10.1B | $9.8B | $0.65 | -- | -- |
| 05/02/2024 | Q1 | $9.1B | $9.5B | $0.83 | -- | -- |
| 12/31/2023 | Q4 | $8.9B | $9.5B | $0.71 | -- | -- |
| 09/30/2023 | Q3 | $8.1B | $8.6B | $0.73 | -- | -- |
| 08/10/2023 | Q2 | -- | $7.9B | $0.63 | -- | -- |
| 05/04/2023 | Q1 | -- | $7.7B | $0.63 | -- | -- |
| 02/02/2023 | Q4 | -- | $6.6B | $0.41 | -- | -- |
| 11/02/2022 | Q3 | -- | $6.2B | $0.43 | -- | -- |
| 08/04/2022 | Q2 | -- | $5.9B | $0.42 | -- | -- |
| 05/12/2022 | Q1 | -- | $6.3B | $0.47 | -- | -- |
| 02/02/2022 | Q4 | -- | $5.9B | $0.37 | -- | -- |
| 11/03/2021 | Q3 | -- | $5.6B | $0.42 | -- | -- |
| 08/04/2021 | Q2 | -- | $5.4B | $0.43 | -- | -- |
| 05/05/2021 | Q1 | -- | $5.5B | $0.44 | -- | -- |
| 02/03/2021 | Q4 | -- | $5.1B | $0.32 | -- | -- |
| 10/30/2020 | Q3 | -- | $4.9B | $0.35 | -- | -- |
| 08/06/2020 | Q2 | -- | $4.4B | $0.33 | -- | -- |
| 05/06/2020 | Q1 | -- | $5B | $0.37 | -- | -- |
| 12/31/2019 | Q4 | -- | $4.8B | $0.27 | -- | -- |
| 09/30/2019 | Q3 | -- | $4.5B | $0.32 | -- | -- |
| 06/30/2019 | Q2 | -- | $4.5B | $0.30 | -- | -- |
| 03/31/2019 | Q1 | -- | $4.5B | $0.33 | -- | -- |
| 12/31/2018 | Q4 | -- | $4.5B | $0.27 | -- | -- |
| 09/30/2018 | Q3 | -- | $4.3B | $0.29 | -- | -- |
| 06/30/2018 | Q2 | -- | $4.4B | $0.34 | -- | -- |
| 03/31/2018 | Q1 | -- | $4.4B | $0.36 | -- | -- |
| 12/31/2017 | Q4 | -- | $4.4B | $0.27 | -- | -- |
| 09/30/2017 | Q3 | -- | $4.2B | $0.31 | -- | -- |
| 06/30/2017 | Q2 | -- | $4.2B | $0.30 | -- | -- |
| 03/31/2017 | Q1 | -- | $4.1B | $0.29 | -- | -- |
| 12/31/2016 | Q4 | -- | $4.3B | $0.25 | -- | -- |
| 09/30/2016 | Q3 | -- | $4.1B | $0.29 | -- | -- |
| 06/30/2016 | Q2 | -- | $4.2B | $0.30 | -- | -- |
| 03/31/2016 | Q1 | -- | $4B | $0.27 | -- | -- |
| 12/31/2015 | Q4 | -- | $4.2B | $0.24 | -- | -- |
Novo Nordisk A/S reported $11.7B worth of top line sales in its most recent quarter.
Novo Nordisk A/S announced earnings per share of $0.70 which represents a beat of analyst forecast a -- per share.
Novo Nordisk A/S reported $8.9B that represents $2.01 per share over the last quarter.
Novo Nordisk A/S's earnings are forecast to grow from $3.28 per share to $2.68 per share next year representing an increase of 18.5%.
Novo Nordisk A/S's next earnings date is February 4, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.